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Glaucoma represents a group of progressive optic neuropathies characterized by gradual loss of retinal ganglion cells (RGCs), the
neurons that conduct visual information from the retina to the brain. Elevated intraocular pressure (IOP) is considered the main
reason for enhanced apoptosis of RGCs in glaucoma. Currently used therapeutic agents are not able to repopulate and/or regenerate
injured RGCs and, therefore, are ineffective in most patients with advanced glaucoma. Accordingly, several new therapeutic
approaches, including stem cell-based therapy, have been explored for the glaucoma treatment. In this review article, we
emphasized current knowledge regarding molecular and cellular mechanisms responsible for beneficial effects of mesenchymal
stem cells (MSCs) and their secretome in the treatment of glaucoma. MSCs produce neurotrophins and in an exosome-
dependent manner supply injured RGCs with growth factors enhancing their survival and regeneration. Additionally, MSCs are
able to generate functional RGC-like cells and induce proliferation of retinal stem cells. By supporting integrity of trabecular
meshwork, transplanted MSCs alleviate IOP resulting in reduced loss of RGCs. Moreover, MSCs are able to attenuate T cell-
driven retinal inflammation providing protection to the injured retinal tissue. In summing up, due to their capacity for
neuroprotection and immunomodulation, MSCs and their secretome could be explored in upcoming clinical studies as new
therapeutic agents for glaucoma treatment.
1. Introduction
Glaucoma, a complex, multifactorial eye disease, is a leading
cause of irreversible blindness affecting more than 70 million
people worldwide [1]. It represents a group of progressive
optic neuropathies characterized by gradual loss of retinal
ganglion cells (RGCs), the neurons that conduct visual infor-
mation from the retina to the brain [2]. An increased produc-
tion and/or decreased outflow of aqueous humor results in
the development of elevated intraocular pressure (IOP)
which is considered the main reason for enhanced apoptosis
of RGCs in glaucoma [2]. Since RGCs are neurons, their
spontaneous regeneration is not feasible, and accordingly,
alleviation of IOP and consequent reduction of RGC loss
are currently the main approach in glaucoma prevention
and therapy [3].
The main target of pharmaceutical and surgical strategies
for glaucoma treatment is trabecular meshwork (TM), an
outflow system located around the base of the cornea that
enables drainage of the aqueous humor [3]. Nevertheless, tra-
ditional TM-directed therapies, which downregulate IOP,
may only delay progression of glaucoma and are not able to
repopulate and/or regenerate RGCs and, therefore, are inef-
fective in most of patients with advanced glaucoma [1, 3].
Accordingly, several new therapeutic approaches have been
investigated for recovering from blindness or for mainte-
nance of remaining vision in glaucoma [4]. Because of their
functional properties, mesenchymal stem cells (MSCs) have
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been the most extensively explored as new therapeutic agents
in the cell-based therapy of glaucoma [3–5]. MSCs produce
neurotrophins which promote survival and regeneration of
injured RGCs in glaucomatous eyes [6]. MSCs are able to
repopulate RGCs by generating functional RGC-like cells
and by promoting expansion and differentiation of residen-
tial retinal stem cells (RSCs) in mature RGCs [7, 8]. Addi-
tionally, MSCs may modulate function of TM cells and
maintain TM integrity enabling alleviation of IOP in glauco-
matous eyes [9].
In this review article, we emphasized current knowledge
and future perspectives regarding molecular and cellular
mechanisms responsible for beneficial effects of MSCs in
the treatment of glaucoma. An extensive literature review
was carried out in February 2019 across several databases
(Medline, Embase, Google Scholar, and ClinicalTrials.gov),
from 1990 to present. Keywords used in the selection were
“mesenchymal stem cells”, “glaucoma”, “retinal ganglion
cells”, “neurotrophins”, “exosomes”, “retinal stem cells”, and
“trabecular meshwork”. All journals were considered, and
the initial search retrieved 253 articles. The abstracts of all
these articles were subsequently reviewed by three of the
authors (CRH, CF, and VV) to check their relevance to the
subject of this manuscript. Eligible studies had to delineate
molecular and cellular mechanisms involved in the MSC-
based therapy of glaucoma, and their findings were analyzed
in this review.
2. Main Text
2.1. Cellular and Molecular Mechanisms Underlying
Glaucoma Development. Based on the etiology, glaucoma
may be classified into primary glaucoma which develops
due to an unknown cause and secondary glaucoma where
there is an identifiable cause of increased eye pressure, optic
nerve damage, and vision loss (tumor, trauma, pigment dis-
persion, pseudoexfoliation, and use of corticosteroids) [1].
A genome-wide association study revealed that the two
main types of glaucoma (closed-angle and open-angle glau-
coma) are distinct genetic entities with different genes associ-
ated with each disease [10]. Mutations in collagen type XI
alpha 1 chain (COL11A1) and pleckstrin homology domain
containing A7 (PLEKHA7) genes were designated as cru-
cially important risk factors for the development of primary
closed-angle glaucoma [10–12]. Collagen type XI is struc-
tural protein of the trabecular meshwork in the eye while
PLEKHA7 protein, expressed in the iris, ciliary body, cho-
roid, and blood-aqueous barrier structures, is involved in
paracellular fluid regulation [13, 14]. Accordingly, mutations
in COL11A1 and PLEKHA7 genes result in increased accu-
mulation of aqueous humor behind the iris which increases
its convexity and causes closure of the angle, site of aqueous
outflow in the eye [2, 13, 14]. Accordingly, closed-angle glau-
coma is manifested by several symptoms such as blurred
vision, sudden sight loss, severe ocular pain, and headache
accompanied by nausea or vomiting [15]. Surgical therapy
directed at widening the angle and preventing further angle
closure is needed for patients suffering from closed-angle
glaucoma [15].
In contrast to closed-angle glaucoma, open-angle glau-
coma may remain asymptomatic until it results in severe
vision impairment [16]. During the early phase, most of
patients have complaints related to the loss of peripheral
vision manifested as missing words when reading or diffi-
culty with driving. The visual acuity is maintained until late
in the disease when apoptotic loss of RGCs significantly
impairs patients’ ability to perform vision-related activities
and reduces quality of life [16].
Mutations of optineurin (OPTN) and myocilin (MYOC)
genes were associated with the enhanced apoptosis of RGCs
in patients with open-angle glaucoma [10–12]. OPTN pro-
tein protects RGCs from apoptosis, and, accordingly, muta-
tions in OPTN gene result in visual impairment due to the
enhanced loss of RGCs [2, 12]. Mutations of MYOC gene
impair intracellular trafficking resulting in enhanced accu-
mulation of misfolded MYOC protein which provokes an
increase of IOP [11, 17]. Elevated IOP, in turn, induces mor-
phological and functional changes in the lamina cribrosa
which provides structural and nutrient support to the RGC
axons as they leave the eye on their path to the brain [18].
Since RGC axons supply the retina with neurotrophic factors
(nerve growth factor (NGF), brain-derived neurotrophic fac-
tor (BDNF), ciliary neurotrophic factor (CNTF), and glial
cell line-derived neurotrophic factor (GDNF)), glaucoma-
tous changes in the lamina cribrosa result in reduced axonal
transport of neurotrophins to RGCs and enhance their apo-
ptotic loss [2, 18].
Since the blood flow in the optic nerve is regulated by
endothelial cells and circulating vasoactive factors, a growing
body of evidence suggested that vascular dysregulation had
an important role in the development and progression of
open-angle glaucoma [19–21]. An altered vascular endothe-
lium function, with an imbalance between endothelium-
derived vasodilators and vasoconstrictors, has been observed
in glaucomatous eyes. Most usually, the level of circulating
endothelin-1 (ET-1) was increased in patients who suffer
from glaucoma [20]. An elevated level of ET-1 and conse-
quent enhanced activation of ET receptors on smooth muscle
cells and pericytes promote influx of calcium and potentiate
its liberation from the internal storages. An increased cyto-
plasmic concentration of calcium induces vasoconstriction
which results in reduced and unstable oxygen supply of the
optic nerve and consequently led to the development of
open-angle glaucoma [21].
It was recently revealed that elevated IOP was involved in
the activation of detrimental immune response in glaucoma-
tous eyes [22]. Even transient elevation of IOP may be suffi-
cient to induce enhanced infiltration of activated T cells in
the retina. These retina-infiltrating T cells are crucially
important for prolonged inflammation and consequent apo-
ptosis of RGCs even when IOP returns to normal [22]. Inter-
estingly, T cells have to be presensitized by commensal
bacteria to become activated. The analysis of T cell receptors
revealed that most of detrimental T cells were specific for
heat-shock proteins (HSPs), alarmins released from injured
retinal cells. An increased serum autoantibodies against
HSPs and retinal deposits of immunoglobulins were
observed in glaucoma patients suggesting the important role
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of HSPs for the induction of detrimental immune response in
glaucomatous eyes [23, 24].
In line with these findings, it is highly expected that ther-
apeutic agents which could protect RGCs from IOP-induced
injury and, at the same time, suppress T cell-driven retinal
inflammation would be able to efficiently prevent glaucoma
progression. Therefore, due to their potential for differentia-
tion in neural lineage cells and capacity for production of
neuroprotective and immunosuppressive factors, MSCs were
designated as potentially new therapeutic agents in the cell-
based therapy of glaucoma.
3. MSCs and Their Secretome as New
Therapeutic Agents in the
Treatment of Glaucoma
MSCs are fibroblast-like, self-renewable cells which reside
in almost all postnatal tissues and organs including bone
marrow, adipose tissue, blood, umbilical cord, amniotic
fluid, dental pulp, and TM [25–28]. In accordance with
the criteria set by the International Society for Cellular
Therapy, a cell population has to fulfill following criteria
to be defined as MSCs: (a) must adhere to plastic in stan-
dard culture conditions; (b) must be able to differentiate
into adipocytes, osteoblasts, and chondrocytes under stan-
dard in vitro differentiating conditions; and (c) more than
95% of the cell population must express CD105 (endoglin,
involved in proliferation, differentiation, and migration),
CD73 (SH3/4, ectoenzyme, regulates the purinergic signal-
ing through the hydrolysis of adenosine triphosphate), and
CD90 (Thy-1, regulates differentiation) and must lack
expression of CD45, CD34, CD14 or CD11b, CD79a or
CD19, and HLA class II, which are membrane markers
of leukocytes, thrombocytes, or erythrocytes [29].
Due to their capacity for differentiation into osteoblasts,
chondrocytes, and adipocytes, MSCs regulate normal turn-
over and maintenance of adult mesenchymal tissues [30].
Importantly, several lines of evidence demonstrated that
MSCs have a differentiation potential broader than initially
thought. Under strictly defined in vitro conditions, MSCs
could differentiate into cells of neuroectodermal origin,
including neuronal cells [30]. Capacity of MSCs to generate
neuron-like cells was one of the main reasons why MSCs
were designated as new therapeutic agents for cell-based
regeneration of RGCs [5]. It was revealed that activation of
Wnt/β-catenin, Notch, and Sonic-hedgehog pathways as well
as inhibition of bone morphogenetic protein 4 (BMP4) sig-
naling in MSCs promoted their differentiation in neuron-
like cells [31]. Among growth factors, epithelium growth
factor (EGF), basic fibroblast growth factor (bFGF), and
hepatocyte growth factor (HGF) have been found effective
in inducing generation of neural phenotype in MSCs
in vitro [31]. In vivo, neural differentiation of MSCs was
limited by their reduced survival due to the suboptimal
availability of neurogenic growth factors [32]. It was
recently showed that induction of autophagy in MSCs prior
to their transplantation may enhance their survival and dif-
ferentiation in neuron-like cells in vivo [27, 33].
MSCs display a variety of adhesion molecules (C-X-C
chemokine receptor type 4 (CXCR-4), CD44, stromal antigen
1 (STAG1), CD166, and CD54/CD102) which enable their
migratory and homing characteristics in the injured eye [5].
Due to the high expression of chemokine receptors and adhe-
sion molecules, MSCs become attracted by HSPs, alarmins,
and inflammatory chemokines (released from injured RGCs
or activated, retinal-infiltrated immune cells), leave their
niches, and migrate towards the site of the injury and
inflammation which suppress detrimental immune response
and promote tissue repair and regeneration [5, 34]. MSCs
suppress inflammatory T cells in a juxtacrine manner
(through the program death (PD) ligand: PD receptor
interaction) or in a paracrine manner, via the production
of soluble immunoregulatory factors (transforming growth
factor-β (TGF-β), HGF, nitric oxide (NO), indoleamine
2,3-dioxygenase (IDO), interleukin 10 (IL-10), interleukin
1 receptor antagonist (IL-1Ra), heme oxygenase- (HO-) 1,
and prostaglandin E2 (PGE2)) (Figure 1) [35].
Differentiation under standard in vitro conditions
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Figure 1: Functional properties of MSCs. MSCs are able to suppress effector T cells in a juxtacrine manner (through the program death (PD)
ligand: PD receptor interaction) or in a paracrine manner, via the production of soluble immunoregulatory factors (transforming growth
factor-β (TGF-β), HGF, nitric oxide (NO), indoleamine 2,3-dioxygenase (IDO), interleukin 10 (IL-10), interleukin 1 receptor antagonist
(IL-1Ra), heme oxygenase- (HO-) 1, and prostaglandin E2 (PGE2)), and differentiate into adipocytes, osteoblasts, and chondrocytes under
standard culture conditions (a). Activation of Wnt/β-catenin, Notch, and Sonic-hedgehog pathways as well as inhibition of bone
morphogenetic protein 4 (BMP4) signaling in MSCs promoted their differentiation in neuron-like cells (b).
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However, it should be noticed that MSCs are not consti-
tutively immunosuppressive. Immediately after engraftment
in injured tissue, MSCs interact with resident immune cells
and, under the influence of local concentration of inflamma-
tory cytokines (TNF-α, IL-1β, and IFN-γ), acquire either
pro- or anti-inflammatory properties. Low levels of TNF-α,
IL-1β, and IFN-γ, during the early phase of inflammation,
induce generation of proinflammatory phenotype in MSCs,
which, in turn, through the production of proinflammatory
cytokines and chemokines promote influx and activation of
circulating phagocytes in injured tissues [5]. Oppositely,
MSCs transplanted in the tissue with high concentration of
TNF-α, IL-1β, and IFN-γ obtain anti-inflammatory pheno-
type and suppress activation and effector functions of
inflammatory macrophages, DCs, NK and NKT cells, and
T lymphocytes, enabling enhanced repair and regeneration
of injured tissue [5]. Activation of toll-like receptors (TLRs)
has a crucially important role for the generation of immuno-
suppressive phenotype in MSCs [5]. TLR priming activates
phosphoinositide 3-kinase (PI3K)/Akt pathway in MSCs
which results in enhanced production of anti-inflammatory
cytokines [11]. Activated TLR-2 and TLR-4 recruit PI3K
which converts phosphatidylinositol 4,5-bisphosphate (PIP2)
to phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 is
involved in activation of Akt, which in turn, inactivates
Glycogen Synthase Kinase 3 (GSK3) and promotes nuclear
accumulation of cAMP Response Element-Binding Protein
(CREB) which displaces p65 subunit of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
from the coactivator of transcription (CREB-binding pro-
tein (CBP)). An increased transcriptional activity of CREB
and consequently reduced transcriptional activity of NF-
κB result in increased production of immunosuppressive
mediators in MSCs [11]. Among MSC-sourced factors,
TGF-β, nitric oxide (NO), indoleamine 2,3-dioxygenase
(IDO), IL-10, IL-6, leukocyte inhibitory factor (LIF),
prostaglandin E2 (PGE2), and IL-1 receptor antagonist
(IL-1Ra) have been mainly attributed to the beneficial
effects of MSCs in attenuation of acute and chronic
inflammation [12].
In line with the above discussed findings, a large number
of experimental studies demonstrated that transplantation of
MSCs and their secretomes efficiently attenuate glaucoma
progression. Beneficial effects of MSCs in the glaucoma treat-
ment mainly relied on their capacity for neurotrophin pro-
duction, differentiation into functional RGCs, and crosstalk
with retinal residential RSCs and TM cells.
4. Therapeutic Potential of MSC-Derived
Neurotrophins in Glaucoma Treatment
Diverse routes of administration determine whether trans-
planted MSCs will efficiently engraft and survive in glauco-
matous eyes [36]. Injury of RGCs, induced by elevated IOP,
is not sufficient to induce breakdown of the blood-retina bar-
rier (BRB) and to enable migration of intravenously (system-
ically) injected MSCs into the retinas of glaucomatous eyes
[36, 37]. On the contrary, the majority of intravitreally trans-
planted MSCs survive in the vitreous body of glaucomatous
eyes several months after injection residing along the inner
limiting membrane (ILM) of the retina, the basement mem-
brane of retinal Müller cells [38]. Müller cells change their
phenotype and function during glaucoma progression which
result in an increased permeability of ILM [39]. Accordingly,
some of intravitreally transplanted MSCs may penetrate ILM
and migrate in close proximity to the nerve fiber and gan-
glion cell layers of the retina, which are the most severely
damaged in glaucoma [38].
Despite the fact that only a very small amount of trans-
planted MSCs could incorporate into the injured retinas
and differentiate into functional RGCs, significant histologi-
cal improvement or functional recovery of damaged RGCs
was usually detected after the intravitreal administration of
MSCs [38]. Accordingly, several lines of evidence demon-
strated that MSCs, in a paracrine manner, promote survival
and endogenous repair of injured RGCs. MSCs are capable
to produce large amounts of neurotrophic factors (NGF,
EGF, bFGF, BDNF, CNTF, and platelet-derived growth fac-
tor (PDGF)) which may increase proliferation and differenti-
ation of retinal progenitor cells, and most of them were able
to efficiently prevent apoptosis and promote survival of
RGCs in glaucomatous eyes [2].
After engraftment in injured retinas, MSCs produce
NGF and BDNF and promote regeneration of RGCs [2,
40, 41]. NGF is a neurotrophic factor involved in the
development, maintenance, and regeneration of mammalian
neurons, having protective effects in optic neuropathies,
including glaucoma [41]. NGF induces enhanced expression
of antiapoptotic Bcl-2 protein and attenuates expression of
proapoptotic Bax protein in RGCs [42]. Compared to healthy
controls, serum levels of NGF were significantly lower in
glaucoma patients [43], indicating that downregulated pro-
duction of NGF might contribute to the enhanced loss of
RGCs. In line with these observations, Lambiase and col-
leagues observed long-lasting improvements in the visual
field, optic nerve function, contrast sensitivity, and visual
acuity in glaucoma patients treated with NGF eye drops,
demonstrating beneficial and neuroprotective effects of exog-
enously administrated NGF in glaucoma therapy [42]. BDNF
is a neurotrophin which is increasingly expressed in the
retinas of glaucomatous eyes [2]. Binding of BDNF to its
receptors (tropomyosin receptor kinase B (TrkB) and the
pan-neurotrophin p75NTR) induces activation of c-jun and
suppression of caspase-2, which prevents apoptosis and pro-
motes survival of RGCs [36]. The serum level of BDNF was
significantly lower in glaucoma patients compared to healthy
controls, and decreased production of BDNF correlated with
reduced survival of RGCs [43]. Nevertheless, effective deliv-
ery of exogenous NTF and BDNF to the glaucomatous eye
is limited by several obstacles including the downregulation
of TrkB receptors after bolus administration [44–46]. Mead
and coworkers addressed these problems by intravitreal
transplantation of dental pulp-derived MSCs (DP-MSCs)
which are engrafted in close proximity to the retina and con-
tinuously delivered NTF and BDNF to injured RGCs pro-
moting their survival and regeneration [47, 48].
Similarly, Johnson and colleagues demonstrated that
intravitreal administration of MSCs efficiently suppressed
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apoptosis and promoted survival of RGCs in a PDGF- and
CNTF-dependent manner [49]. MSC-derived PDGF
induced phosphorylation and activation of signal trans-
ducer and activator of transcription 3 (STAT-3) in RGCs
which downregulated the expression of proapoptotic Bax
and consequently reduced apoptotic loss of RGCs [6].
Anti-PDGF treatment prevented the expression of STAT-
3 and completely inhibited MSC-based suppression of Bax
in RGCs [6], indicating an important role of MSC-derived
PDGF for survival of RGCs [6, 49]. In a similar manner
as PDGF, MSC-derived CNTF reduced apoptotic loss of
RGCs in glaucomatous eyes by promoting phosphorylation
of cytoplasmic STAT-3 [50]. Nevertheless, it has to be
highlighted that significant visual impairment was noticed
in healthy rat eyes injected with a high dose of CNTF
[51], suggesting that intraocular levels of CNTF need to
be continuously monitored and controlled during MSC-
based therapy to prevent detrimental effects of high con-
centration of CNTF on vision function.
In line with these findings, several lines of evidence
demonstrated that beneficial effects of neurotrophins were
dependent on their continuous release [52–54]. Since
MSCs home to the site of retinal injury and are able to
produce NGF, BDNF, CNTF, and PDGF in an injury-
dependent manner, these stem cells were used as vehicles
for continuous delivery of neurotrophins in the glaucoma
treatment [36]. Harper and colleagues engineered BDNF-
overexpressing MSCs (MSCsBDNF). Intravitreally trans-
planted MSCsBDNF better survived in glaucomatous rat
eyes and provided significantly improved functional and
structural protection to RGCs than genetically nonmodified
MSCs [40], indicating therapeutic potential of MSCsBDNF in
cell-based treatment of glaucoma. A similar approach was
used by Harrell and coworkers who engineered NGF-
overexpressing MSCs (MSCsNGF) [5]. Intravitreally injected
MSCsNGF were successfully engrafted in the injured retinas
and promoted RGC survival and regeneration in a NGF-
dependent manner, indicating therapeutic potential of
MSCsNGF in glaucoma therapy [55].
5. MSC-Derived Exosomes as Nanocarriers for
Neurotrophin Delivery to the Injured RGCs
MSCs hold great potential in regenerative ophthalmology
due to their capacity for secretion of exosomes (Exos), mem-
brane enclosed, nanosize (30-100nm), extracellular vesicles
that contain messenger ribonucleic acid (mRNA), micro-
RNA (miRNA), and proteins, including neurotrophins [5].
MSC-derived Exos (MSC-Exos) are able to reside in the vit-
reous humor at least for four weeks after intravitreal admin-
istration and, due to their nanodimension, may rapidly reach
RGCs to supply them with neurotrophins [56]. As demon-
strated by Mead and Tomarev [57], cell death of RGCs was
significantly reduced in animals treated with BM-MSC-
Exos. By delivering BDNF, NGF, and PDGF to RGCs, BM-
MSC-Exos provided neuroprotection which significantly
reduced the total number of degenerating axons in optic
nerves of glaucomatous eyes [58]. Importantly, these benefi-
cial effects were observed only in animals that received MSC-
derived Exos and were not noticed after intravitreal injection
of fibroblast-derived Exos, indicating specific therapeutic
potential of MSC-Exos in RGC regeneration and glaucoma
treatment [59].
Interestingly, therapeutic effects of BM-MSC-Exos were
significantly better than those obtained after transplantation
of BM-MSCs. BM-MSCs lack the capacity to integrate into
the retina and remain in the vitreous body after injection
[37, 57]. On the contrary, BM-MSC-Exos diffused rapidly
throughout the retina, and within one hour after injection,
intravitreally administered BM-MSC-Exos were able to suc-
cessfully deliver neurotrophins to the injured RGCs pro-
moting their survival and regeneration [5, 56, 57].
However, it has to be noted that therapeutic efficacy of
BM-MSC-Exos was only observed when BM-MSC-Exos
were intravitreally injected every week or every month.
Longer delays between treatments completely abrogated
MSC-Exo-dependent effects, suggesting that their beneficial
effects were temporary and relied on their repetitive injec-
tion [59]. On the contrary, BM-MSCs remain in the glauco-
matous eyes months after intravitreal injection and,
accordingly, may provide long-lasting neuroprotection due
to the continuous release of neurotrophins.
MSC-Exos elicited their therapeutic effects through
miRNA-dependent mechanisms. It was shown that knock-
down of Argonaute2 protein, which is crucially important
for miRNA function, significantly attenuated BM-MSC-
Exo-induced effects [59]. RNA sequencing revealed that
more than 40 miRNAs were upregulated in BM-MSC-Exos,
compared to fibroblast-derived Exos, and among them,
miR-17-92, miR-21, and miR146a were designated as the
most important for regeneration of RGCs in glaucomatous
eyes [5, 57, 58]. The expression of phosphatase and tensin
homolog (PTEN), which is an important suppressor of
RGC axonal growth and survival, was regulated by miR-17-
92 and miR-21 while miR-146a modulated expression of
epidermal growth factor receptor (EGFR) involved in inhi-
bition of axon regeneration [5].
6. Dental Pulp and Amniotic Fluid as Valuable
and Easily Accessible Sources for MSC-Based
Therapy of Glaucoma
MSCs develop distinct functional characteristics in response
to the microenvironment to which they are exposed [60].
Accordingly, Mead and colleagues compared human DP-
MSCs, bone marrow-derived MSCs (BM-MSCs), and adi-
pose tissue-derived MSCs (AT-MSCs) for their potential to
promote regeneration of injured RGCs in glaucomatous eyes
[61]. Among compared subpopulations of human MSCs,
DP-MSCs produced the largest amounts of neurotrophic fac-
tors (PDGF, NGF, GDNF, and BDNF) and most efficiently
protected RGCs against apoptosis (Figure 2). Similar findings
were obtained in vivo, in the animal model of RGC injury
where intravitreally transplanted DP-MSCs promoted a sig-
nificantly greater increase in RGC survival and significantly
higher increase in the number of regenerating axons com-
pared with similarly injected BM-MSCs [47]. Based on all
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these results, dental pulp has been proposed as a valuable and
easily accessible source of DP-MSCs which could be used in
autologous cell-based therapy of glaucoma [48].
In line with these findings, Roozafzoon and colleagues
induced differentiation of DP-MSCs into functional RGCs
by using RGC differentiation medium and a three-
dimensional fibrin network as an environment which mim-
icked mechanical properties of the native retina [7]. Isolated
DP-MSCs were initially differentiated on 150 lg/ml poly-D-
Lysine and 1 lg/ml Laminin substrate for 11 days in a differ-
entiation Dulbecco’s modified Eagle medium/Nutrient
Mixture F-12 (DMEM/F12) medium containing 1% N2 sup-
plement, 0.5% fetal bovine serum (FBS), 2 lg/ml heparin, and
10ng/ml bFGF. Afterwards, the cells were grown in
DMEM/F12 medium supplemented with growth factors
(500 ng/ml Sonic-hedgehog (Shh) and 8ng/ml bFGF) for
additional 16 hours. Immunocytochemical and gene expres-
sion analysis revealed increased expression of RGC specific
transcriptional factors (Pax6, Atoh7, and BRN3B) in differ-
entiated cells [7], indicating successful differentiation of
DP-MSCs in RGC-like cells.
In addition to dental pulp, amniotic fluid also contains a
variety of growth factors that are crucial for the development
of RGCs [62]. Additionally, amniotic fluid serves as a rich
and advantageous source of amniotic fluid-derived MSCs
(AF-MSCs) which, similar as DP-MSCs, exhibited greater
capacity for cell proliferation, self-renewal, and differentia-
tion in neural cells than BM-MSCs [63, 64]. AF-MSCs more
rapidly formed neurospheres in vitro, showed higher expres-
sion of neural stemness markers following neural stem cell
differentiation (Nestin, vimentin, and Musashi), and have
higher capacity for production of BDGF and NGF [64].
It was recently revealed that Exos derived from AF-MSCs
contain immunosuppressive factors TGF-β and HGF which
suppress proliferation of activated T cells by causing the G1
cell cycle arrest [65–67]. Interestingly, AF-MSC-Exos selec-
tively downregulated Janus kinase/Stat signaling pathways
in inflammatory T cells without affecting expansion and
immunosuppressive properties of CD4+CD25+FoxP3+ T
regulatory cells [68], indicating their therapeutic use in the
treatment of T cell-driven inflammatory diseases, including
glaucoma. In line with these findings, we recently developed
neuroprotective and immunomodulatory ophthalmic solu-
tion (“Exosome-Derived Multiple Allogeneic Protein Para-
crine Signaling (Exosomes D-MAPPS)”) which activity is
based on the capacity of AF-MSC-derived exosomes to pro-
duce neurotrophins (PDGF, NGF) and immunomodulatory
factors (TGF-β, HGF) enabling tissue repair in neurodegen-
erative and inflammatory eye diseases [5, 67, 68].
7. Crosstalk between MSCs and Residential
Retinal Cells in MSC-Based
Alleviation of Glaucoma
Although it was well documented that MSC-derived neuro-
trophins were responsible for beneficial effects of trans-
planted MSCs on survival of injured RGCs [52–54],
recently published data indicated that interaction between
transplanted MSCs and residential retinal cells also contrib-
utes to the MSC-based alleviation of glaucoma [5, 31–33].
Several lines of evidence demonstrated that dysfunction
and degeneration of TM are the main factors responsible
for the development of elevated IOP in glaucomatous eyes
[69–74]. Apoptosis and oxidative stress induce a reduced
number of TM cells while TGF-β-driven fibrosis provokes
remodeling of the extracellular matrix and induces an
increase in aqueous humor outflow resistance that led to
the elevation of IOP and consequent development of glau-
coma [71–74]. Accordingly, therapeutic agents which
DP-MSCs
RGCs
DMEM/F12 medium containing 1% N2 supplement,
0.5% fetal bovine serum (FBS),
2 lg/ml heparin and 10 ng/ml bFGF (for 11 days)
and DMEM/F12 medium supplemented with
500 ng/ml Sonic hedgehog
and 8 ng/ml bFGF for additional 16 hours
(a)
DP-MSCs
Intravitreal transplantation of DP-MSCs
PDGF
NGF
GDNF
BDNF
RGCs
Attenuates apoptosis of RGCs
(b)
Figure 2: Therapeutic potential of DP-MSCs in glaucoma treatment. Dental pulp represents valuable and easily accessible sources for DP-
MSCs which are able to differentiate into functional retinal ganglion cells (RGCs) under appropriate culture conditions (a). Intravitreally
transplanted DP-MSCs produce several neurotrophic factors (platelet-derived growth factor (PDGF), nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF)) which promote survival of RGCs and induce
regeneration of injured axons (b).
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support TM integrity could prevent increase of IOP and alle-
viate glaucoma progression. Interestingly, MSCs and TM
cells shared several phenotypic and functional characteristics
[75]. Similar to MSCs, TM cells expressed CD73, CD90,
CD105, and CD146 and lack expression of CD31, CD34,
and CD45. Additionally, the expression of transcriptional
factors responsible for cell potency and proliferation (sox2
and notch1) was detected in TM cells as it was observed in
DP-MSCs and AF-MSCs [75].
In addition to this data, Tay and colleagues managed to
isolate MSCs from TM area (TM-derived MSCs; TM-MSCs)
[28]. TM-MSCs had spindle-shaped morphology, express
CD73, CD90, CD105, and CD146, and were capable to differ-
entiate into adipocytes, chondrocytes, and osteocytes [28].
TM-MSCs also express Ankyrin3, Low-Density Lipoprotein
Receptor, Chitinase3-Like-1, Human Milk Fat Globule 1,
Matrix Metalloproteinase 1 (MMP1), and Aquaporin 1 which
are present in mature TM cells, suggesting that TM-MSCs are
progenitors of the meshwork tissue which are able to effi-
ciently replace injured TM cells. Accordingly, isolation of
TM-MSCs from glaucoma patients and their subsequent
autologous transplantation represent a potentially new thera-
peutic strategy for cell-based therapy of glaucoma that should
be explored in future experimental and clinical studies [28].
Importantly, it should be highlighted that mature, fully
differentiated TM cells have different phenotypic and func-
tional properties than TM-MSCs. In contrast to TM-
MSCs, mature TM cells could not differentiate into adipo-
cytes or osteocytes and had high expression of α-smooth
muscle actin, myocilin, and angiopoietin-like 7 which reg-
ulate TM integrity and collagen synthesis [28, 75]. Accord-
ingly, several research groups investigated whether MSCs
and/or their secretomes alleviated glaucoma by regulating
function of mature TM cells [9, 76, 77]. Roubeix and col-
leagues demonstrated that injection of BM-MSCs in the
anterior chamber of hypertensive rat eyes significantly
attenuated IOP by modulating function of TM cells in a
paracrine manner [9]. The significant increase in the total
number of functional RGCs was noticed in glaucomatous
eyes that received either MSCs or MSC-derived condi-
tioned medium (MSC-CM). MSC-CM-based therapy man-
aged to activate antiapoptotic pathways in TM cells in an
Akt-dependent manner and induced decreased myosin
phosphorylation which resulted in relaxation of TM cells,
reduced aqueous humor outflow resistance, and attenuated
IOP. Moreover, MSC-CM suppressed activation of TGF-β
signaling and attenuated collagen production in TM cells
[9]. Similar results were reported by Manuguerra-Gagné
and colleagues who demonstrated that injection of MSCs
and their secretomes completely restored TM functionality
in laser-treated eyes [76]. Interestingly, attenuated IOP
were only observed in glaucomatous eyes that received
low-oxygen pretreated MSCs while no significant effect
on glaucoma progression was observed after injection of
normoxic MSCs [76]. Preconditioning by brief hypoxia
provoked enhanced expression of hypoxia-inducible factor
1 (HIF-1) in MSCs [27]. HIF-1 is a master regulator of
adaptive responses to hypoxia that activates autophagy-
related mitogenic neuropeptide Apelin and prevents apo-
ptosis. Accordingly, enhanced expression of HIF-1 in
low-oxygen pretreated MSCs enabled their better adapta-
tion to hypoxia-induced stress [27, 77]. These MSCs were
capable to better engraft and survive in the TM area in a
paracrine manner, modulating TM integrity by suppress-
ing collagen synthesis in TM cells as well as through the
activation of neural progenitors and residential RSCs [76].
RSCs, which generate all the neurons of the mature
retina, reside in the ciliary margin area of the retina and,
therefore, were designated as pigmented cells from the cil-
iary margin (PCMs) [78]. The total number of RSCs in
adult mammalian eyes is insufficient for optimal regenera-
tion of RGCs in glaucomatous eyes [79]. Since the ciliary
margin area is very small and proliferation ability of
PCMs is limited, only a small number of patients’ own
PCMs may be isolated and used for autologous transplan-
tation [78, 80]. Recently, Li and colleagues revealed that
coculture of PCMs with BM-MSCs significantly increased
the proliferation rate of PCMs and notably enhanced their
differentiation in functional RGCs [8]. Major markers of
retinal differentiation, including rhodopsin, visual system
homeobox 2, heparin sulfate, and photoreceptor-specific
homeobox gene (cone-rod homeobox, Crx), were remark-
ably upregulated in PCMs following coculture with BM-
MSCs, indicating that BM-MSC-based priming of PCMs
should be further explored as a new approach which could
enable autologous transplantation of RGCs in glaucoma
patients [8].
8. Clinical Use of MSCs in the
Therapy of Glaucoma
Although encouraging results related to the MSC-based
therapy of glaucoma were obtained in a large number of
preclinical studies, there is still no evidence that transplan-
tation of MSCs may repopulate RGCs, attenuate IOP, and
restore visual function in patients suffering from glaucoma.
Three clinical studies (NCT02330978, NCT01920867, and
NCT03011541) were aimed at demonstrating safety and effi-
cacy of MSC-based therapy in glaucoma, but none of them
have been completed yet.
De Paula and colleagues planned to investigate whether
intravitreal transplantation of autologous BM-MSCs could
show beneficial effects in patients suffering from advanced
glaucoma (NCT02330978). Although the estimated study
completion date was December 2016, obtained results
are still not published and the current status of this study
is unknown.
Two other clinical trials (NCT01920867 and
NCT03011541) will be conducted by Weiss and coworkers
who are going to evaluate the use of autologous BM-
derived stem cells for the treatment of retinal and optic nerve
diseases, including glaucoma. BM-derived stem cells will be
delivered by different routes (intravitreally, intravenously,
and intraocular with vitrectomy prior to intraocular injection
which may result in a larger amount of stem cells in the intra-
vitreal cavity). Patients will be followed for one year with
serial comprehensive eye examinations including imaging
and diagnostic ophthalmic testing. Since these studies still
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recruit patients and estimated study completion dates are
August 2019 (for NCT01920867) and January 2021 (for
NCT03011541), it is expected that obtained results will be
published in upcoming years.
9. Conclusions
In summing up, results obtained in a large number of exper-
imental studies revealed that beneficial effects of MSCs and
their secretome in glaucoma therapy relied on their capacity
for neuroprotection and RGC regeneration. Through the
production of neurotrophins and vasoactive and immuno-
modulatory factors, MSCs induce expansion and regenera-
tion of RGCs, provide maintenance of TM integrity, and
attenuate retinal inflammation in animal models of glaucoma
(Table 1). Nevertheless, it has to be highlighted that thera-
peutic potential of MSCs and their secretome in the treat-
ment of glaucoma has not been validated in clinical settings
yet. The optimal origin, number, and route of administration
as well as safety of MSC-based therapy still have to be deter-
mined in clinical trials with the appropriate number of
enrolled patients. Accordingly, the conclusion that MSCs
and their secretome represent new human remedy for the
treatment of glaucoma can be made only if MSC-dependent
therapeutic effects will be confirmed in future clinical trials.
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